NCT04022616 Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
| NCT ID | NCT04022616 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ohio State University Comprehensive Cancer Center |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 99 participants |
| Start Date | 2010-06-04 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 99 participants in total. It began in 2010-06-04 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * Ability to give informed consent * Stage I-III breast malignancy Exclusion Criteria: * Unable to tolerate venipuncture
Contact & Investigator
William Carson, MD
PRINCIPAL INVESTIGATOR
Ohio State Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT04022616 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04022616 currently recruiting?
Yes, NCT04022616 is actively recruiting participants. Contact the research team at OSUCCCClinicaltrials@osumc.edu for enrollment information.
Where is the NCT04022616 trial being conducted?
This trial is being conducted at Columbus, United States.
Who is sponsoring the NCT04022616 clinical trial?
NCT04022616 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is William Carson, MD at Ohio State Comprehensive Cancer Center. The trial plans to enroll 99 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.